🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Germany / NCT05111834
Active, not recruiting Not applicable

IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms

NCT05111834 · tracked via the Priya Life Science Germany tracker
Phase
Not applicable
Started
2021-09-15
Last updated
2025-02-03

Condition(s) studied

Graft Vs Host Disease

Investigational drug(s) / intervention(s)

Supervised resistance training plus nutritional endorsementNutritional endorsement

Supervised resistance training plus nutritional endorsement: resistance training 2x per week, nutritional endorsement/therapy based on individual needs

Nutritional endorsement: nutritional endorsement/therapy based on individual needs

Study summary

The IRENE-G trial is a randomized controlled study that aims to investigate the effect of a supervised resistance exercise program (2x/week for 24 weeks) in combination with a nutritional intervention on physical performance/frailty in patients with GvHD symptoms treated with high dose steroids.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Existing or new diagnosis of acute or chronic GvHD treated with systemic steroid therapy (≥0,5 mg/kg/day) * Sufficient German language skills * Willing/ able to train at the provided exercise facilities or online twice a week * Willing/ able to take part in the scheduled testing * Capacity to consent * Signed informed consent Exclusion Criteria: * Any physical or mental conditions that would hamper the adherence to the training and/or nutritional program or the completion of the study procedures * Heart insufficiency \> NYHA III or uncertain arrhythmia * Uncontrolled hypertension * Severe renal dysfunction (GFR \< 30%, Creatinine\> 3mg/dl) * Reduced standing or walking ability * Insufficient hematological capacity (either hemoglobin value below 8 g/dl or thrombocytes below 30.000/µL) * Any other comorbidities that preclude participation in the exercise programs

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Heidelberg University Hospital Heidelberg Germany

More University Hospital Heidelberg trials in Germany

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05111834 on ClinicalTrials.gov ↗ ← All trials in Germany